Cervical Cancer: Study on Molecular Landscape and Protein Biomarkers. Current Diagnostic and Therapeutic Capabilities

Dear Colleagues,

Cervical cancer is still the leading gynecologic health problem globally. The association between certain high-risk strains of Human Papilloma Virus (HPV) and cervical cancer is well established. Although HPV is essential to the transformation of cervical epithelial cells, it is not sufficient, and a variety of cofactors and molecular events influence whether cervical cancer will develop. Even though screening programs and vaccine-driven prevention have substantially changed the landscape for cervical cancer, many questions still remain unanswered.

Universal vaccination against HPV is typically the basic initial population procedure. Next in line is properly conducted screening based on sensitive and specific tests. This step is one of the main targets of conducted studies, which focus on seeking new tests or methods or a combination of already known ones. Finally, as we currently try to offer our patients tailored, precise and personalized treatment, researchers search for molecular treatment options as well as markers of prognostic and predictive value.

In our Special Issue, we would like to focus on diagnostic and therapeutic capabilities regarding cervical cancer on the basis of experimental studies as well as review papers showing the state of the art in this field.

Dr. Christopher Kobierzycki
Prof. Dr. Piotr Dzięgiel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.